TY - JOUR
T1 - Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor
T2 - A case report
AU - Miura, Naoko
AU - Matsubara, Taichi
AU - Takamori, Shinkichi
AU - Haratake, Naoki
AU - Toyozawa, Ryo
AU - Yamaguchi, Masafumi
AU - Seto, Takashi
AU - Taguchi, Kenichi
AU - Takenoyama, Mitsuhiro
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/5/23
Y1 - 2020/5/23
N2 - The transformation of adenocarcinoma to small cell lung cancer has been reported as acquisition of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. We here report a patient who presented histologically confirmed transformation of adenocarcinoma to small cell lung cancer after treatment with immune checkpoint inhibitor. A 65-year-old man was treated with pembrolizumab as first-line therapy and achieved temporarily a stable disease with progression after six cycles of this agent. At that stage, a transbronchial biopsy showed small cell lung cancer, and he was found to have high serum concentrations of neuron-specific enolase despite concentrations of numerous tumor markers, including neuron-specific enolase, having been within normal limits at the time of presentation. The patient thereafter was treated as a small cell carcinoma patient using cisplatin plus irinotecan and amrubicin.
AB - The transformation of adenocarcinoma to small cell lung cancer has been reported as acquisition of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. We here report a patient who presented histologically confirmed transformation of adenocarcinoma to small cell lung cancer after treatment with immune checkpoint inhibitor. A 65-year-old man was treated with pembrolizumab as first-line therapy and achieved temporarily a stable disease with progression after six cycles of this agent. At that stage, a transbronchial biopsy showed small cell lung cancer, and he was found to have high serum concentrations of neuron-specific enolase despite concentrations of numerous tumor markers, including neuron-specific enolase, having been within normal limits at the time of presentation. The patient thereafter was treated as a small cell carcinoma patient using cisplatin plus irinotecan and amrubicin.
UR - http://www.scopus.com/inward/record.url?scp=85090448169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090448169&partnerID=8YFLogxK
U2 - 10.1093/omcr/omaa026
DO - 10.1093/omcr/omaa026
M3 - Article
AN - SCOPUS:85090448169
VL - 2020
JO - Oxford Medical Case Reports
JF - Oxford Medical Case Reports
SN - 2053-8855
IS - 4-5
M1 - omaa026
ER -